Lifesci Capital Has Pessimistic Outlook of DBVT Q3 Earnings

DBV Technologies S.A. (NASDAQ:DBVT) – Equities researchers at Lifesci Capital lowered their Q3 2025 EPS estimates for DBV Technologies in a report issued on Wednesday, July 30th. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($1.25) per share for the quarter, down from their prior estimate of ($0.70). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share. Lifesci Capital also issued estimates for DBV Technologies’ Q4 2025 earnings at ($1.25) EPS, FY2025 earnings at ($5.40) EPS and FY2026 earnings at ($1.65) EPS.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.34). The firm had revenue of $1.74 million for the quarter, compared to analyst estimates of $0.64 million. DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%.

Several other equities research analysts also recently issued reports on DBVT. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research note on Tuesday, May 27th. HC Wainwright upped their price objective on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, May 5th. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a report on Friday, July 18th. The Goldman Sachs Group upgraded shares of DBV Technologies to a “sell” rating and set a $7.25 target price on the stock in a report on Thursday, May 29th. Finally, JMP Securities reissued a “market outperform” rating and set a $21.00 target price on shares of DBV Technologies in a research report on Thursday, June 26th. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, DBV Technologies presently has an average rating of “Moderate Buy” and an average price target of $14.75.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $9.00 on Friday. The firm’s 50 day moving average price is $9.50 and its two-hundred day moving average price is $7.41. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $12.78. The stock has a market cap of $246.51 million, a price-to-earnings ratio of -1.89 and a beta of -0.58.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent reporting period. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.